Vonoprazan acetate is under clinical development by Jiangsu Carephar Pharmaceutical and currently in Phase II for Duodenal Ulcer. According to GlobalData, Phase II drugs for Duodenal Ulcer have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vonoprazan acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vonoprazan acetate overview
Vonoprazan acetate is under development for the treatment of peptic ulcer including gastric ulcer and duodenal ulcer. The drug candidate is a potassium-competitive acid blocker (P-CAB) and is administered as an injection.
For a complete picture of Vonoprazan acetate’s drug-specific PTSR and LoA scores, buy the report here.